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OBJECTIVE — The purpose of this study was to assess incidence of and risk factors for
recurrent cardiovascular disease (CVD) in type 2 diabetes.
RESEARCH DESIGN AND METHODS — We estimated the incidence of recurrent
cardiovascular events in type 2 diabetic patients, aged 40–97 years, followed by a network of
diabetes clinics. The analysis was conducted separately for 2,788 patients with CVD at enroll-
ment (cohort A) and for 844 patients developing the ﬁrst episode during the observation period
(cohort B).
RESULTS — During 4 years of follow-up, in cohort A the age-adjusted incidence of a recur-
rentevent(per1,000person-years)was72.7(95%CI58.3–87.1)inmenand32.5(21.2–43.7)
inwomen,whereasincohortBitwas40.1(17.4–62.9)inmenand22.4(12.9–32.0)inwomen.
After controls were included for potential predictors (familial CVD, obesity, smoking, diabetes
duration, glycemic control, microvascular complications, geographic area, and antihypertensive
and lipid-lowering treatment), male sex, older age, and insulin use were signiﬁcant independent
risk predictors (cohort A) and serum triglyceride levels 1.69 mmol/l emerged as the only
metabolic (negative) prognostic factor (cohort B). In both cohorts, a prior CVD episode, espe-
cially myocardial infarction, was by far the strongest predictor of recurrent CVD.
CONCLUSIONS — Approximately 6% of unselected diabetic patients in secondary preven-
tion develop recurrent major CVD every year. Those with long-standing previous CVD show a
higher incidence of recurrence. Male sex, age, high triglyceride levels, and insulin use are
additional predictors of recurrence.
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P
reventing relapses of cardiovascular
disease (CVD) in patients with pre-
vious CVD is a daunting task for cli-
nicians. The clinical and socioeconomic
impact of recurrence is such that many
healthcaresystemsregardsecondarypre-
vention as worthy of free prescription of
expensive medications. Nonetheless, rel-
atively little is known of the natural
historyofthismanifestationofatheroscle-
roticcardiovasculardisease.Althoughitis
generally assumed that the pattern and
riskfactorsforrelapsesarethesameasfor
ﬁrstCVDevents,tothebestofourknowl-
edge, detailed analyses of this phenome-
non are lacking.
Patients with type 2 diabetes have
recurrent CVD disease with a high fre-
quency. Previous studies have concen-
tratedonsurvivalorrecurrentCVDaftera
ﬁrst myocardial infarction. Thus, the Fra-
mingham Study reported that the risk of
recurrent myocardial infarction was
higherindiabeticwomenthanindiabetic
men (1). In the Finnish contribution to
the World Health Organization Multina-
tional Monitoring of Trends and Deter-
minants of Cardiovascular Disease (FIN-
MONICA) study, the 1-year mortality in
type 2 diabetic patients who had survived
apreviousmyocardialinfarctionwas44%
in men and 37% in women (2). In 169
diabetic patients with prior myocardial
infarction, Haffner et al. (3) reported sex-
and age-adjusted incidence rates (per
1,000person-years)of78fatalornonfatal
myocardial infarctions, 34 strokes, and
73 cardiovascular deaths. In the largest
observationalcohortoftype2diabeticpa-
tientswithpriormyocardialinfarctionre-
ported thus far (n  1,215), i.e., the
placebo arm of the Prospective Pioglita-
zone Clinical Trial in Macrovascular
Events (PROactive study) (4), the inci-
denceofarecurrentcompositeendpoint,
including nonfatal myocardial infarction,
coronary revascularization, acute coro-
nary syndrome, and cardiac death, was
6.5% per year. However, because this
population consisted of patients selected
with criteria typical of clinical trials, some
caution is needed in generalizing the
study’s ﬁndings.
The objective of the present study was
to describe incidence of and risk factors for
recurrent CVD, including stroke and limb
amputations, in a large, unselected cohort
of diabetic patients receiving standard care
who had previously had a CVD event.
RESEARCH DESIGN AND
METHODS— The present analysis
wasperformedaspartoftheDiabetesand
Informatics(DAI)study,amulticenterco-
hort study conducted by the DAI Study
Group (DIAINF) together with the Italian
Association of Clinical Diabetologists
(AMD) and the Italian National Institute
of Health (ISS) since September 1998.
The aim of the DAI study was to evaluate
the prevalence and incidence of CVD
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disease [IHD], percutaneous coronary in-
tervention angioplasty [PTCA], coronary
artery bypass graft [CABG], stroke, and
peripheralamputations)amongtype2di-
abetic patients regularly attending hospi-
tal-based diabetes clinics. In Italy, a
public network of 700 diabetes clinics
provides care for up to 80% of patients
with known diabetes, delivering diagnos-
tic conﬁrmation, therapy, prevention,
and early diagnosis of acute and chronic
complications through close patient fol-
low-up by a team of specialists and the
scheduling of regular checkups. Most pa-
tients are referred to these care units by
their general practitioner, and care is free
of charge. A detailed description of the
DAI study methodology has been pre-
sented elsewhere (5). For the incidence
study, 157 clinics participated, with a to-
tal of 14,432 patients: 11,644 patients
free of CVD at enrollment and 2,788 pa-
tients who entered the study with a
known prior CVD event. The recurrence
of CVD events, described herein, was an-
alyzed in the 2,788 patients with a prior
CVD event (cohort A) and in the 844 of
the 11,644 patients without events at en-
rollment who developed their ﬁrst CVD
event during the observation period (co-
hort B).
Data collection and deﬁnitions
The data used in this analysis were col-
lectedinfourwavesoffollow-upbetween
2000 and 2003. During the enrollment
and follow-up visits, a standard question-
naire was used to collect, in addition to
anthropometric data, information on life-
style habits, drug therapy, laboratory
measures (speciﬁed below), clinical his-
tory, microvascular complications (reti-
nopathy, blindness, and foot ulcers), and
cardiovascular complications. For pa-
tients who did not appear for the sched-
uled visits, information, including death,
was obtained through telephone inter-
views with the patient, a relative, or the
primary care physician.
Thefollowingtestswereperformedat
enrollment and at each follow-up visit.
Plasma glucose, A1C, and lipid proﬁle
were determined in the fasting state. A1C
was measured at each clinic, not in a cen-
tralized laboratory; for this reason, glyce-
mic control was estimated as the percent
increment of the individual patient’s A1C
above the upper limit of the normal range
of the local laboratory. Urinary albumin
excretion (UAE) was obtained in a timed
overnight collection; microalbuminuria
was deﬁned as UAE of 30–300 mg/l in at
least three successive measurements in
theabsenceofotherknowncausesofpro-
teinuria. Hypertension was deﬁned as
systolic blood pressure 140 mmHg
and/or diastolic blood pressure 90
mmHg and/or antihypertensive treat-
ment.Retinopathywasassessedbyacom-
prehensive dilated eye examination and
by the acquisition of high-quality stereo-
scopic photographs assessed by an oph-
thalmologist.FamilialCVDwasidentiﬁed
when the patient had a ﬁrst-degree rela-
tive (parent, sibling, or child) who had
had a major cardiovascular event at age
55years.Alcoholconsumptionwascal-
culated in equivalent milliliters of wine
and transformed to grams per week (0
g/week, no consumption; 1–225 g/week,
moderate consumption; and 226
g/week, high consumption).
CVD events
Study events were all major IHD events
(myocardial infarction, PTCA, and
CABG), minor IHD events (angina and
otherformsofIHD),stroke,andlimbam-
putations. Patients were classiﬁed as hav-
ing IHD if they had one of the following:
1) a history of hospital admission for ei-
ther fatal or nonfatal myocardial infarc-
tion or an episode of angina; 2) a 12-lead
electrocardiogram with positive results
for prior myocardial infarction or angina
bytheMinnesotacodingsystem(criteriaI
1–3, IV 1–3, V 1–2, and VII 1); or 3)a
history of CABG or PTCA. All patients
had had at least one electrocardiogram in
the 12 months preceding enrollment to
exclude prior myocardial infarction.
Stroke was deﬁned according to World
Health Organization criteria for con-
ﬁrmed and possible stroke (i.e., a clinical
syndromeconsistingofarapidlydevelop-
ingneurologicaldeﬁcitpersistingfor24
h or leading to death, in the absence of
other diseases that could explain the
symptoms). A hospital discharge record
or a specialist visit was required to certify
the event.
ACVDeventwasconsideredasrecur-
rentifitoccurredatleast28daysafterthe
ﬁrst event. A minor IHD event after an-
otherminororamajorIHDeventwasnot
counted as a bona ﬁde recurrent event,
i.e.,anewepisode.Similarly,amajorIHD
event after a minor IHD event was not
considered as recurrent. Such episodes
were collectively indicated as events not
classiﬁable as recurrent, in contrast with
the truly recurrent CVD events. This
choice was made on the grounds that,
very often, angina and a subsequent myo-
cardial infarction or revascularization are
consequences of the same arterial lesion.
Statistical analysis
The analysis was conducted separately in
thetwostudycohorts(AandB).Thevari-
ables considered in the analyses were
those collected at enrollment for cohort A
and those collected at the follow-up visit
atwhichtheﬁrstCVDeventwasreported
for cohort B.
Data for the continuous variables are
expressed as means  SD or median (in-
terquartile range) for non-normal vari-
ables and as proportions for categorical
variables. The incidence density of recur-
rent CVD events was standardized on the
basis of the age distribution of the 1998
Italian population.
Univariate and multivariate Cox pro-
portional hazards models were used to
examine the risk factors for recurrent
events. Preliminary data analysis was per-
formed with univariate Cox models of all
covariates: duration of diabetes, waist cir-
cumference, BMI, total cholesterol level,
HDL cholesterol level, triglyceride level,
A1C,bloodpressurelevel,alcoholintake,
smoke,familialCVD,microvascularcom-
plication, lipid-lowering treatment, anti-
hypertensive treatment, and treatment of
diabetes. The interaction between blood
pressure level and antihypertensive treat-
ment and between total cholesterol level
and lipid-lowering therapy was evalu-
ated. For cohort A, the overall model was
alsoadjustedbythenumberofyearsfrom
the ﬁrst event to the enrollment to par-
tially consider the patient’s history of
CVD preceding the beginning of the
study. All covariates with P  0.1 (P 
0.05incohortB,giventhesmallersample
size) were entered into the ﬁnal multivar-
iate models. All analyses were performed
using the Stata 8.0 statistical package.
RESULTS— Duringthe4-yearfollow-
up, in cohort A, 414 of 2,788 patients
(whohadenteredthestudywithaknown
previous CVD event) developed at least
an event that fulﬁlled the stipulated crite-
ria of a recurrent event. In cohort B, 54 of
844 patients (who had had their ﬁrst
event during the study) had a recurrent
event. With regard to multiple events, 38
patientsincohortAand4incohortBhad
two recurrent events, and only 1 patient
in cohort A had three recurrent events.
Eventsoccurringin386patientsofcohort
A and 46 patients of cohort B were not
included in the analysis because they did
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rent events (almost all IHD events).
As summarized in Table 1, the study
population consisted of a high proportion
of elderly patients with rather good glyce-
mic control. The most common CVD risk
factor was hypertension, which was found
in almost all patients. In cohort A, patients
with recurrent events were older, were
more often male with a previous history of
microvascular complications, and had
more use of insulin and lipid-lowering
medications. In cohort B, patients with re-
current events had higher total cholesterol
and triglyceride levels, more often had a
previous history of microvascular compli-
cations, myocardial infarction, or amputa-
tion, and had more use of insulin.
Of note, the age-standardized inci-
dencerateofrecurrentCVDwas40%lower
in cohort B than in cohort A (Table 2). The
average time between enrollment and the
occurrence of the recurrent event in cohort
Awas1.61.04years,whereasincohortB
the average time between the ﬁrst and re-
current event was 1.5  0.8 years. The av-
erage time between the ﬁrst and the
recurrent event in cohort A was 1.6 1.04
years,whereastheaveragetimebetweenthe
ﬁrst and the recurrent event was 8.1  6.9
years in cohort A and 1.5  0.8 years in
cohort B.
In cohort A, the standardized inci-
dence of recurrent episodes was 89.2 per
1,000 person-years (95% CI 71.3–107.2)
among patients with a major IHD event,
Table 1—Clinical characteristics of patients with type 2 diabetes in the two study cohorts by presence of recurrent events
Characteristics
Cohort A Cohort B
No recurrent
event
With event not
classiﬁable as
recurrent
With recurrent
event
No recurrent
event
With event not
classiﬁable as
recurrent
With recurrent
event
n 1,988 386 414 744 46 54
Age (years) 68  86 9  86 9  86 7  86 6  76 7  9
BMI (kg/m
2) 29  52 8  42 8  42 9  53 0  52 9  4
Waist circumference (cm) 99  12 98  11 99  11 99  11 99  10 98  10
Total cholesterol (mmol/l) 5.53  1.11 5.56  1.45 5.53  1.06 5.40  1.09 5.56  1.03 5.69  1.34
HDL cholesterol (mmol/l) 1.24  0.34 1.24  0.31 1.22  0.36 1.29  0.36 1.24  0.28 1.27  0.39
LDL cholesterol (mmol/l) 3.47  0.96 3.47  0.96 3.49  0.91 3.36  0.93 3.49  0.85 3.41  0.98
Diabetes duration (years) 10 (4–16) 11 (5–17) 11 (5–17) 11 (6–17) 11 (7–18) 14 (6–20)
Systolic blood pressure
(mmHg) 145 (135–160) 145 (135–160) 135 (145–160) 140 (130–160) 150 (140–165) 140 (130–160)
Diastolic blood pressure
(mmHg) 80 (80–90) 80 (80–90) 80 (80–90) 80 (80–90) 80 (80–90) 80 (80–90)
Plasma glucose (mmol/l) 9.0 (7.4–11.0) 8.8 (7.2–10.9) 8.6 (7.2–10.8) 8.8 (7.2–10.6) 8.9 (8.0–10.3) 8.7 (7.4–11.1)
Triglycerides (mmol/l) 1.63 (1.19–2.25) 1.54 (1.14–2.24) 1.63 (1.22–2.26) 1.52 (1.11–2.04) 1.32 (1.06–2.21) 1.73 (1.13–2.25)
Men 56.3 51.3 68.6 50.0 50.0 46.3
Hypertension* 91.2 91.2 92.8 89.1 95.7 92.5
A1C† 80.0 76.5 76.7 80.3 82.2 82.7
Alcohol intake 38.5 41.5 40.8 45.4 47.5 43.2
Smoking
Current 10.2 12.4 10.9 11.6 13.0 3.7
Former 29.3 24.6 36.2 23.4 28.3 24.1
Familial CVD 39.0 38.9 43.5 28.0 23.9 22.2
Microvascular complications 45.3 44.0 52.9 49.5 58.7 61.1
Lipid-lowering treatment 24.0 27.2 31.2 32.8 43.9 38.5
Diabetes treatment
Diet alone 11.9 12.7 7.7 8.3 4.3 4.0
Oral agents 64.7 59.3 58.7 60.1 67.4 56.0
Insulin  oral agents 9.8 12.7 13.1 9.6 8.7 12.0
Insulin 13.6 15.3 20.5 22.0 19.6 28.0
Geographic area
Northern Italy 54.7 55.7 61.1 55.4 39.1 59.3
Central Italy 10.3 8.0 9.7 10.9 13.1 11.1
Southern Italy and Islands 35.0 36.3 29.2 33.7 47.8 29.6
Onset event
Minor IHD event 41.3 58.8 10.4 58.3 84.8 31.5
Major IHD event 38.3 37.1 63.8 25.3 15.2 44.4
Stroke 12.9 — 15.0 9.9 — 11.1
Amputation 3.0 — 2.1 4.2 — 11.1
Other‡ 4.5 4.1 8.7 2.3 0.0 1.9
Data are means  SD, median (interquartile range), or %. *Deﬁned as systolic pressure 140 mmHg and/or diastolic pressure 90 mmHg and/or antihypertensive
treatment. †Percentage of patients with values higher than the upper limit of the normal range. ‡Any combination of events.
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nor IHD event, 49.2 (35.5–62.9) among
thosewithapriorstroke,and79.8(36.0–
123.5) among those with amputation or
combined events. A multivariate Cox
model for cohorts A and B is shown in
Table 3. In cohort A, age, male sex, and
use of insulin, alone or in combination
with oral agents, were independent pre-
dictors of recurrence. However, having
had a major IHD event as the ﬁrst event
was the strongest factor of all, with stroke
and combined events also being powerful
predictors, whereas time between ﬁrst
and recurrent events did not make a sig-
niﬁcant independent contribution. In co-
hort B, the risk factor pattern was similar
to that of cohort A, with prior events car-
rying the highest risk. In this model, the
only metabolic factor with an indepen-
dent risk prediction was a serum triglyc-
eride level 1.69 mmol/l. No interaction
between blood pressure level and antihy-
pertensive treatment or between total
cholesterol level and lipid-lowering ther-
apy was found in either cohort.
Given the dominant role of the ﬁrst
event as a predictor, the multivariate
models were also run after excluding this
variable. In cohort A, some difference
emerged: receiving lipid-lowering ther-
apy (hazard ratio [HR] 1.32 [95% CI
1.07–1.63]), number of years from ﬁrst
event (1.57, [1.21–2.03] for 6 years),
and living in Southern Italy (0.77 [0.62–
0.96]) became signiﬁcant. In cohort B no
signiﬁcant difference from the full model
was found. Finally, given its value from
the clinician point of view (although not
considered in our analysis of recurrent
events), we report the standardized inci-
dence of a minor IHD event: 39.5 per
1,000 person-years (95% CI 30.3–48.7)
inmenand57.1(36.7–77.5)inwomenin
cohort A and 21.3 (5.7–36.8) in men and
8.3 (2.4–14.3) in women in cohort B.
CONCLUSIONS— In our popula-
tion of diabetic patients receiving usual
care, we found that every year, 6.1% of
the patients with a prior CVD event de-
velopedanewmajoratheroscleroticcom-
plication. This percentage compares very
well with those (5.9–6.0% per year) of
thecohortsofdiabeticpatientsinsecond-
ary prevention analyzed in the PROactive
(4) study and the Scandinavian Simvasta-
tin Survival Study (4S) (7). A higher rate
of 7.6% per year was reported in the
Drugs and Evidence-Based Medicine in
the Elderly (DEBATE) study (8), but that
study was performed in subjects with a
higher mean age (80 years).
Theincidencerateofrecurrentevents
in cohort B was almost half that of cohort
A. Likely explanations of this difference
are that among cohort B patients, there
were more women, age was somewhat
younger, familial CVD was less prevalent,
and prior myocardial infarction was less
frequent relative to prior stroke. More-
over, and more importantly, these pa-
tients had a shorter and more recent CVD
history and were observed for only 1.7
year on average. The patients in cohort A,
on the other hand, were “survivors” of a
CVD event that preceded the recurrent
event by a longer span of time; in fact,
there was a remarkable difference in
terms of number of years from ﬁrst and
recurrent event, which could be the ex-
planation for this different outcome.
Our analysis highlighted features that
can be useful in clinical practice. First,
men had markedly higher rates of recur-
rent events than women. This result may
beduetothegreaterpredispositiontone-
crotic events of men than of postmeno-
pausal women, who are more prone to
nonmyocardial infarction IHD (angina)
and,probably,heartfailure(9–11).Inthe
Framingham study, after the onset of an-
gina, men had a twofold greater risk than
women for both myocardial infarction
and coronary death after adjustment for
age and IHD risk factors (1). We de-
scribed this sex effect previously in the
prevalence (5) and incidence analyses of
theﬁrstIHDevent(12)andstroke(13)in
the DAI population. In the present study,
ontheotherhand,theincidenceofminor
IHD in cohort A was higher in women
than in men.
Second, in the search for risk factors
speciﬁc to recurrent major CVD, we
found that age played an important role,
with a 10-year difference translating into
a 26% risk increment. The impact of age
as a CVD risk factor in the general popu-
lationiswellknown(14–18),butthecur-
rentﬁndingsdocumentthefactthatageis
an independent risk factor for relapsing
majorCVDinapopulationofdiabeticpa-
tients not selected for age.
Thefactthatuseofinsulin,aloneorin
combination with oral agents, was an in-
dependent risk factor for recurrence in
cohort A should not be overlooked. This
ﬁnding was also reported in the PROac-
tive cohort of type 2 patients with prior
myocardial infarction who developed a
second fatal or nonfatal myocardial in-
farction (4) and in the Cardiovascular
Health Study (19), in which insulin was
found to be associated with greater CVD
mortality compared with oral agents. The
association was true also when serum in-
sulin concentrations were measured (20).
IntheDAIstudy,insulintreatmentwasan
independent risk factor for IHD (12) and
stroke (13) in patients free of CVD at
baseline as well. On the other hand, the
adverse prognosis associated with insulin
use may be regarded as the result of an
“indication bias”: more severe, longer-
standing diabetes is preferentially treated
withinsulinandhasaworsecardiovascu-
lar prognosis (21,22). In fact, in clinical
trials such as the Diabetes Control and
Complications Trial in type 1 diabetic pa-
tients and the UK Prospective Diabetes
Study(UKPDS)intype2diabeticpatients
(23,24), insulin treatment had a clear-cut
antiatherogeniceffect.Therefore,thepos-
sibility that prolonged use of insulin in
these type 2 diabetic patients resulted in
less cardioprotection than control of gly-
cemia by other pharmacological means
cannot be ruled out.
Dyslipidemia, as indicated by a
higher frequency of lipid-lowering treat-
ment in cohort A and higher serum tri-
glyceridelevelsincohortB,emergedasan
independent risk predictor. This ﬁnding
resonates with the previous observation
Table 2—Crude and age-adjusted incidence rates of recurrent events in diabetic men and
women with type 2 diabetes in the two study cohorts
No.
patients
No.
cases* Person-years Crude IR (95% CI) Adjusted IR (95% CI)
Cohort A
Men 1,602 284 3,847.8 73.8 (65.7–82.9) 72.7 (58.3–87.1)
Women 1,186 130 2,945.4 44.1 (37.2–52.4) 32.5 (21.2–43.7)
All 2,788 414 6,793.2 60.9 (55.3–67.1) 57.6 (47.3–67.8)
Cohort B
Men 424 29 693.6 41.8 (29.1–60.2) 40.1 (17.4–62.9)
Women 420 25 724.1 34.5 (23.3–51.1) 22.4 (12.9–32.0)
All 844 54 1,417.8 38.1 (29.2–49.7) 33.0 (18.1–48.1)
Data are incidence rate (IR) per 1,000 person-years (95% CI). *Patients with at least one recurrent event.
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ide levels are a signiﬁcant predictor of the
ﬁrst IHD event in women without prior
CVD.
The dominant observation in the DAI
study seemed to be the strong impact of
the type of the ﬁrst CVD events on relaps-
es—an observation that emerged from
both study cohorts. Having had a major
IHD event, alone or combined with an-
other CVD event, was associated with the
highestrelativerisk,possiblyleavinglittle
room for other modiﬁable factors.
A limitations of this study is the lack
of centralized laboratory measurements.
Also, given the fact that the observation
period was relatively short, there may not
have been time for other potentially sig-
niﬁcant factors to emerge. Finally, infor-
mation on other potential risk predictors
such as lipoprotein levels, postprandial
glucose excursions, or genetic markers
was lacking. The strength of this study, in
addition to the large size, is that it pro-
vides a detailed description of the burden
of secondary CVD prevention in diabetic
patients under real-life conditions. Be-
cause in Italy the percentage of patients
who seek care at the hospital-based dia-
betes clinics is very high (up to 80% of
patientswithknowndiabetes),ourresults
can be conﬁdently extrapolated to the en-
tire type 2 diabetic population in the
country.
In summary, this nationwide obser-
vationalstudyoutlinesthenaturalhistory
of recurrent events in type 2 diabetic pa-
tients managed by usual care. The ob-
served risk proﬁle has signiﬁcant clinical
implications. First, diabetic patients, es-
pecially elderly men, whose CVD onset is
myocardialinfarctionorrevascularization
(or combined events) warrant close fol-
low-up and intensive management. Sec-
ond, patients using insulin show a higher
frequency of recurrent events. Third,
diabetic patients with high triglycerides
levels may be targeted by aggressive treat-
ment in secondary CVD prevention.
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